RT Book, Section
A1 Chikwe, Joanna Y.
A1 Castillo, Javier G.
A2 Fuster, Valentin
A2 Harrington, Robert A.
A2 Narula, Jagat
A2 Eapen, Zubin J.
SR Print(0)
ID 1161731758
T1 TRICUSPID AND PULMONARY VALVE DISEASE
T2 Hurst's The Heart, 14e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071843249
LK accesscardiology.mhmedical.com/content.aspx?aid=1161731758
RD 2024/04/23
AB Mild  tricuspid  valve  disease  is  common,  and  usually  clinically  silent.1  Moderate  and  severe  tricuspid  regurgitation,  however,  are  increasingly  recognized  as  an  important  marker  of  morbidity  and  mortality.2  By  far  the  commonest  etiology  is  secondary  or  functional  tricuspid  regurgitation,  where  the  valve  leaflets  are  structurally  normal,  and  regurgitation  is  primarily  a  result  of  annular  dilatation  in  the  setting  of  right  or  left  heart  dysfunction  or  dilatation,  or  pulmonary  hypertension.3  Secondary  tricuspid  regurgitation  is  a  very  dynamic  lesion,  commonly  seen  in  patients  with  left-sided  valvular  disease,  ischemic  heart  disease,  or  atrial  fibrillation.  Primary  tricuspid  disease  is  most  commonly  a  result  of  endocarditis,  carcinoid  heart  disease,  or  rheumatic  valve  disease,  with  lead-  and  catheter-related  pathology  from  cardiac  devices  as  an  increasingly  recognized  cause.  Apart  from  congenital  lesions  involving  the  pulmonary  valve  or  the  right  ventricular  infundibulum  and  carcinoid  heart  disease,  pulmonary  valve  disease  as  an  acquired  condition  in  adults  is  extremely  rare.  The  pulmonary  valve  is  the  least  commonly  involved  in  infectious  processes  such  as  rheumatic  fever  and  bacterial  endocarditis.